TNFSF10 and neoplasm: In summary, future preclinical and clinical studies investigating the implementation of the death inducing ligand TRAIL in clinical combination therapy protocols should not only take into account the critical signaling steps of TRAIL cell death induction but the impact of p53 status of the individual tumor cell on TRAIL sensitivity.